Navigation Links
Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX

Affymetrix Inc. (Nasdaq: AFFX), announced today the launch of the new GeneChip(R) Globin-Reduction kits and associated protocol developed in conjunction with PreAnalytiX -- a joint venture between QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company). The new kits optimize the PreAnalytiX PAXgene(TM) Blood RNA System for use with Affymetrix GeneChip technology and improve gene expression profile results of cellular RNA extracted from whole blood.

The combination of the GeneChip Blood RNA Concentration Kit (featuring the PAXgene Blood RNA System) and the GeneChip Globin-Reduction RNA Controls standardizes all the steps of whole blood RNA processing -- from sample stabilization to analysis on GeneChip microarrays. This has been a major challenge in expression studies of whole blood, as prior RNA preparation methods have often yielded expression results with variable levels of sensitivity.

Use of the Globin-Reduction Protocol and associated reagent kits enables researchers to detect subtle changes in gene expression by reducing the overwhelming amounts of globin messenger RNA (mRNA) present in whole blood. Large amounts of globin mRNA can significantly interfere with gene expression assay results. High globin mRNA levels contributed from a fraction of the red blood cells have typically masked the less abundant, but more important, changes of gene expression associated with white blood cells, such as lymphocytes and monocytes. Counteracting the effects of globin mRNA during target preparation significantly increases assay sensitivity on GeneChip arrays.

The GeneChip Globin Reduction Protocol links PreAnalytiX' already proven standard for whole blood collection, stabilization and isolation of RNA with Affymetrix' leading product line for microarray-based analysis of whole blood cellular RNA profiles.

"An accurate picture of in vivo gene expression profiles is essential for understanding gene regul ation as it relates to different disease states and a patient's response to drug therapy," said Noel Doheny, Vice President of PreAnalytiX and QIAGEN. "We continue to see a strong market trend towards the correlation of gene expression profiles of whole blood and tissue samples. With the new GeneChip Globin-Reduction Protocol and associated reagent kits, standardization of the entire pre-analytical and analytical process for whole blood gene expression profiling can now be accomplished."

"The ability of the PAXgene(TM) Blood RNA system to preserve RNA expression levels from the time of sample collection to the time of RNA isolation is a critical component to obtaining accurate gene expression profiles," said Lianne McLean, Sr. Director, Gene Expression Marketing, Affymetrix. "The optimized protocol, the PAXgene system and the controls will significantly improve the ability to obtain high quality profiles from blood, thus enabling clinical research and collecting samples for multi-site clinical trials."

About PreAnalytiX GmbH:

The purpose of PreAnalytiX GmbH, a Swiss-based joint venture between BD (Becton, Dickinson and Company) and QIAGEN N.V., is to develop, manufacture, and market integrated systems for the collection, stabilization, and purification of nucleic acids (DNA and RNA) for molecular diagnostic testing. The first product from PreAnalytiX, the PAXgene(TM) Blood RNA System, was launched in April 2001, and has set a new standard for stabilizing whole blood cellular RNA profiles at the time of blood collection in an evacuated blood collection tube. This enables researchers and clinicians to perform more accurate analysis of gene expression profiles without the variations caused by sample collection, storage, transport or fractionation while relying on highly standardized and proven sample collection principles. Additional information on PreAnalytiX can be found under http://www.preanalytix.com .

About Affymetrix:

Affy metrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and over 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 900 employees worldwide.


'"/>

Source:Affymetrix


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
6. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
11. IMF Launches World’s First DNA Database for Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology: